Related references
Note: Only part of the references are listed.Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia
Mike Dennis et al.
BLOOD (2015)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Herve Dombret et al.
BLOOD (2015)
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
Hartmut Doehner et al.
BLOOD (2014)
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Martin Reck et al.
LANCET ONCOLOGY (2014)
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival
Alan K. Burnett et al.
BLOOD (2013)
The Leukemia-associated Mll-Ell Oncoprotein Induces Fibroblast Growth Factor 2 (Fgf2)-dependent Cytokine Hypersensitivity in Myeloid Progenitor Cells
Chirag A. Shah et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)
Gert J. Ossenkoppele et al.
BLOOD (2012)
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
Isamu Okamoto et al.
MOLECULAR CANCER THERAPEUTICS (2010)
An open-label, Phase I study of cediranib (RECENTIN™) in patients with acute myeloid leukemia
Walter Fiedler et al.
LEUKEMIA RESEARCH (2010)
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
Gunnar Juliusson et al.
BLOOD (2009)
Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group
Thomas Buechner et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
Frank Hilberg et al.
CANCER RESEARCH (2008)
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
Alan K. Burnett et al.
CANCER (2007)
Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity
L. Zahiragic et al.
LEUKEMIA (2007)
Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors
Emma Kulimova et al.
MOLECULAR CANCER THERAPEUTICS (2006)
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
FJ Giles et al.
LEUKEMIA RESEARCH (2006)
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia
T Büchner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Activation of FGFR1β signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells
M. A. Karajannis et al.
LEUKEMIA (2006)
Leukemia-stimulated bone marrow endothelium promotes leukemia cell survival
J. Pedro Veiga et al.
EXPERIMENTAL HEMATOLOGY (2006)
Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia
T Padró et al.
LEUKEMIA (2002)
Platelet-derived growth factor (PDGF) in human acute myelogenous leukemia:: PDGF receptor expression, endogenous PDGF release and responsiveness to exogenous PDGF isoforms by in vitro cultured acute myelogenous leukemia blasts (vol 67, pg 267, 2001)
B Foss et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2001)
Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias
S Dias et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration
S Dias et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Share Paper
